Back to top
more

Puma Biotechnology (PBYI)

(Delayed Data from NSDQ)

$2.94 USD

2.94
302,018

-0.01 (-0.34%)

Updated Nov 4, 2024 03:59 PM ET

After-Market: $2.94 0.00 (0.00%) 4:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Dr. Reddy's (RDY), COYA Ink Deal to Develop COYA 302 for ALS

by Zacks Equity Research

Dr. Reddy's (RDY) enters into a licensing agreement with Coya Therapeutics to develop and commercialize the latter's ALS investigational combination therapy, COYA 302.

Travere (TVTX) Up on Latest Portfolio Updates & Reorganization

by Zacks Equity Research

Travere (TVTX) to submit an sNDA to the FDA to convert the accelerated approval for Filspari to full approval for IgAN in first-quarter 2024. The company is implementing a strategic reorganization to cut costs. Stock rises.

PBYI or TECH: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

PBYI vs. TECH: Which Stock Is the Better Value Option?

J&J (JNJ) Announces 2024 and Long-Term Financial Outlook

by Zacks Equity Research

J&J (JNJ) expects operational sales growth in the range of 5-6% in 2024, driven by both its Innovative Medicine and MedTech divisions.

Bristol Myers' (BMY) Opdivo sBLA Gets FDA's Priority Review

by Zacks Equity Research

Bristol Myers (BMY) announces that the FDA has accepted its sBLA for Opdivo to treat first-line adult patients with unresectable or metastatic bladder cancer under priority review.

Alterity (ATHE) Up on Preclinical Parkinson's Treatment Data

by Zacks Equity Research

Data from a preclinical study shows that treatment with Alterity's (ATHE) lead candidate improved motor performance and general function in monkeys with experimentally-induced Parkinson's disease.

Vanda (VNDA) Rises as FDA Accepts NDA for Gastroparesis Drug

by Zacks Equity Research

The FDA accepts Vanda's (VNDA) new drug application ("NDA") for tradipitant for treating the symptoms of gastroparesis. The company's shares rise in after-hours trading.

J&J's (JNJ) Bladder Cancer Drug Gets FDA's Breakthrough Tag

by Zacks Equity Research

FDA grants Breakthrough Therapy Designation to J&J's (JNJ) TAR-200 for high-risk non-muscle-invasive bladder cancer based on data from the phase IIb SunRISe-1 study.

Is it a Good Idea to Invest in AC Immune (ACIU) Stock Now?

by Zacks Equity Research

Here, we discuss some reasons why investing in AC Immune (ACIU) stock now may turn out to be a prudent move.

Apellis (APLS) Rides on Syfovre to Fuel Growth Amid Rivalry

by Zacks Equity Research

Apellis' (APLS) marketed products, Syfovre and Empaveli, continue to remain the growth drivers since launch. However, stiff competition in the target markets remains a woe.

AstraZeneca (AZN) to Discontinue Two Studies on Lokelma

by Zacks Equity Research

Owing to increased enrollment timelines and low event rates, AstraZeneca (AZN) plans to stop the STABILIZE-CKD and DIALIZE-Outcomes phase III evidence studies for the hyperkalemia drug Lokelma.

Acadia (ACAD) Begins Study on ACP-101 for Hyperphagia in PWS

by Zacks Equity Research

Acadia (ACAD) begins late-stage development of carbetocin nasal spray for the treatment of hyperphagia in Prader-Willi syndrome.

Here Is Why Bargain Hunters Would Love Fast-paced Mover Puma Biotech (PBYI)

by Zacks Equity Research

Puma Biotech (PBYI) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Seagen's (SGEN) Combo Drug Expanded-Use sBLA Gets Priority Tag

by Zacks Equity Research

Seagen (SGEN) and Astellas Pharma announce that the FDA has accepted the label expansion-seeking application for the Padcev/Keytruda combo under priority review to treat first-line bladder cancer.

AbbVie (ABBV) Posts Encouraging Data From Lung Cancer Study

by Zacks Equity Research

Data from a mid-stage study on AbbVie's (ABBV) experimental ADC drug demonstrates compelling clinical benefits across key endpoints in certain lung cancer patients.

FDA Accepts Karuna's (KRTX) NDA Filing for Schizophrenia Drug

by Zacks Equity Research

If approved, Karuna's (KRTX) KarXT will be the first new mechanism of action to treat schizophrenia in several decades. A final decision is expected in September 2024.

Adaptimmune (ADAP) Rises as GSK Transfers T-Cell Therapy IND

by Zacks Equity Research

Adaptimmune (ADAP) shares rise as GSK transfers IND for letetresgene autoluecel (lete-cel), which is being developed for treating synovial sarcoma and myxoid/round cell liposarcoma.

BioVie (BIVI) Falls 61% Despite Upbeat Alzheimer's Study Data

by Zacks Equity Research

BioVie (BIVI) stock plunges 61% in spite of positive phase III Alzheimer's Disease study results due to significant study conduct violations and protocol deviations reported by the company.

Vaishali Doshi headshot

4 Top-Performing Liquid Stock Picks for Robust Returns

by Vaishali Doshi

Here are four top-ranked liquid stocks, Puma Biotechnology (PBYI), Amphastar Pharmaceuticals (AMPH), DropBox (DBX), and Vimeo (VMEO), which investors can add to their portfolio for solid gains.

Acadia (ACAD) Begins Alzheimer's Disease Psychosis Study (Revised)

by Zacks Equity Research

Acadia (ACAD) initiates a phase II study on ACP-204 in the treatment of Alzheimer's disease psychosis, the first among the three studies planned in the phase II/III clinical program of the candidate.

Emergent (EBS) Gets $75M BARDA Contract for Anthrax Vaccine

by Zacks Equity Research

The BARDA is exercising an option to procure additional doses of Emergent BioSolutions' (EBS) recently approved anthrax vaccine. Deliveries will likely be completed by the end of first-quarter 2024.

Immunovant (IMVT) Up on Positive Initial IMVT-1402 MAD Study Data

by Zacks Equity Research

Immunovant (IMVT) posts encouraging initial results from the 600 mg MAD cohort of its early-stage study on IMVT-1402. Stock rises.

SpringWorks (SWTX) Rises on FDA Nod for Desmoid Tumor Drug

by Zacks Equity Research

The FDA approves SpringWorks' (SWTX) Ogsiveo (nirogacestat) for the treatment of adult patients with desmoid tumors. Shares rise.

AbbVie (ABBV) Lymphoma Drug Gets FDA Breakthrough Therapy Tag

by Zacks Equity Research

The FDA grants breakthrough therapy designation to AbbVie's (ABBV) Epkinly in follicular lymphoma indication. The EMA validates a regulatory filing seeking label expansion for the drug.

Xenon (XENE) Up on Top-Line Data From MDD Drug Phase II Study

by Zacks Equity Research

Xenon (XENE) posts top-line data from a phase II proof-of-concept study evaluating its pipeline candidate, XEN1101, for treating moderate-to-severe major depressive disorder. Stock rises.